- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02585934
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
November 8, 2018 updated by: Axovant Sciences Ltd.
A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease
This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This Phase 3 study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) on both cognition and activities of daily living when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease after 24 weeks of double-blind treatment.
This study will also provide further information on the safety and tolerability of the 35-mg dose of intepirdine (RVT-101) when used in combination with donepezil compared to donepezil alone.
This study is being conducted under the agreement of a Special Protocol Assessment by FDA.
Subjects completing this study will be eligible to enroll in a 12 month open-label study of RVT-101 (RVT-101-3002) in which concomitant medications for the treatment of Alzheimer's disease including memantine will be allowed.
Study Type
Interventional
Enrollment (Actual)
1315
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, B1828CKR
- AR101
-
Buenos Aires, Argentina, C1199ABB
- AR060
-
Ciudad Autónoma de Buenos Aire, Argentina, C1405BCK
- AR040
-
Ciudad Autónoma de Buenos Aire, Argentina, C1425AHQ
- AR081
-
Ciudad Autónoma de Buenos Aire, Argentina, C1012AAR
- AR084
-
Ciudad Autónoma de Buenos Aire, Argentina, C1058AAJ
- AR027
-
Ciudad Autónoma de Buenos Aire, Argentina, C1111AAL
- AR012
-
Ciudad Autónoma de Buenos Aire, Argentina, C1117ABH
- AR160
-
Ciudad Autónoma de Buenos Aire, Argentina, C1406BOA
- AR028
-
Ciudad Autónoma de Buenos Aire, Argentina, C1428AQK
- AR035
-
Cordoba, Argentina, X5000DCE
- AR051
-
Cordoba, Argentina, X5000FJF
- AR137
-
Mendoza, Argentina, M5501ACP
- AR210
-
Mendoza, Argentina, M5502AHV
- AR219
-
Santiago del Estero, Argentina, G4200DND
- AR059
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina, A1902AJU
- AR130
-
La Plata, Buenos Aires, Argentina, B1900BOM
- AR041
-
-
-
-
-
Caulfield, Australia, VIC3162
- AU227
-
Chermside, Australia, QLD 4032
- AU079
-
Heidelberg West, Australia, VIC 3081
- AU032
-
Herston, Australia, QLD 4209
- AU062
-
Hornsby, Australia, NSW 2077
- AU011
-
West Perth, Australia, WA 6005
- AU138
-
-
-
-
-
Ruse, Bulgaria, 7003
- BU125
-
Sofia, Bulgaria, 1431
- BU131
-
Sofia, Bulgaria, 1632
- BU198
-
Varna, Bulgaria, 9000
- BU073
-
-
-
-
Alberta
-
Medicine Hat, Alberta, Canada, T1B4E7
- CA151
-
-
British Columbia
-
Kamloops, British Columbia, Canada, V2C 1K7
- CA120
-
Kelowna, British Columbia, Canada, V1Y 1Z9
- CA054
-
Kelowna, British Columbia, Canada, V1Y 4N7
- CA188
-
Penticton, British Columbia, Canada, V2A 5C8
- CA186
-
West Vancouver, British Columbia, Canada, V7T 2Z3
- CA141
-
-
Ontario
-
Newmarket, Ontario, Canada, L3Y 5G8
- CA147
-
North York, Ontario, Canada, M3B 2S7
- CA196
-
Toronto, Ontario, Canada, M4G 0A1
- CA237
-
-
Quebec
-
Gatineau, Quebec, Canada, J8T8JI
- CA236
-
-
-
-
II Región
-
Antofagasta, II Región, Chile, 1270244
- CH212
-
-
Region Metropolitana
-
Santiago, Region Metropolitana, Chile, 7560356
- CH076
-
-
Región Metropolitana
-
Santiago, Región Metropolitana, Chile, 7510186
- CH061
-
Santiago, Región Metropolitana, Chile, 7520338
- CH075
-
-
-
-
-
Zagreb, Croatia, 10000
- CR069
-
Zagreb, Croatia, 10000
- CR122
-
Zagreb, Croatia, 10090
- CR070
-
Zagreb, Croatia, 10090
- CR068
-
Zagreb, Croatia, 10090
- CR083
-
-
-
-
-
Praha 10, Czechia, 100 00
- CZ128
-
Praha 10, Czechia, 109 00
- CZ207
-
Praha 2, Czechia, 120 00
- CZ132
-
Praha 6, Czechia, 160 00
- CZ129
-
Rychnov nad Kneznou, Czechia, 516 01
- CZ161
-
-
-
-
-
Lille Cedex, France, 59037
- FR231
-
Marseille Cedex 5, France, 13385
- FR182
-
Paris Cedex, France, 75013
- FR221
-
Villeurbanne, France, 69 100
- FR202
-
-
-
-
-
Bad Homburg, Germany, 61348
- GE206
-
Berlin, Germany, 10117
- GE091
-
Berlin, Germany, 12203
- GE071
-
Berlin, Germany, 13125
- GE139
-
Cologne, Germany, 50937
- GE230
-
Ellwangen, Germany, 73479
- GE252
-
Leipzig, Germany, 04107
- GE180
-
Mannheim, Germany, 68165
- GE228
-
Munchen, Germany, 81675
- GE017
-
Nürnberg, Germany, 90402
- GE157
-
Ulm, Germany, 89081
- GE098
-
Westerstede, Germany, 26655
- GE251
-
-
-
-
-
Brescia, Italy, 25125
- IT053
-
Cefalù, Italy, 90015
- IT124
-
Pavia, Italy, 27100
- IT030
-
Perugia, Italy, 06156
- IT103
-
Roma, Italy, 00168
- IT072
-
Roma, Italy, 00189
- IT029
-
Roma, Italy, 00179
- IT183
-
Rome, Italy, 00185
- IT175
-
Torino, Italy, 10 126
- IT085
-
-
-
-
-
Busan, Korea, Republic of, 49201
- SK066
-
Seoul, Korea, Republic of, 06351
- SK067
-
Seoul, Korea, Republic of, 07061
- SK190
-
-
-
-
-
Bialystok, Poland, 15-756
- PO013
-
Bydgoszcz, Poland, 85-080
- PO024
-
Bydgoszcz, Poland, 85-796
- PO010
-
Katowice, Poland, 40-123
- PO107
-
Katowice, Poland, 40-749
- PO092
-
Krakow, Poland, 30-349
- PO023
-
Krakow, Poland, 35-505
- PO025
-
Poznan, Poland, 61-853
- PO009
-
Szczecin, Poland, 70-111
- PO014
-
Warszawa, Poland, 01-697
- PO074
-
-
-
-
-
Belgrade, Serbia, 11 000
- SE164
-
Belgrade, Serbia, 11000
- SE090
-
Belgrade, Serbia, 11000
- SE166
-
Belgrade, Serbia, 11000
- SE193
-
Kragujevac, Serbia, 34000
- SE155
-
Novi Knezevac, Serbia, 23330
- SE031
-
Vrsac, Serbia, 26300
- SE165
-
-
-
-
-
Singapore, Singapore, 119074
- SI052
-
Singapore, Singapore, 308433
- SI026
-
-
-
-
-
Banska Bystrica, Slovakia, 97404
- SL056
-
Bratislava, Slovakia, 820 07
- SL192
-
Dubnica nad Váhom, Slovakia, 01841
- SL200
-
Kosice, Slovakia, 040 17
- SL191
-
Krompachy, Slovakia, 05342
- SL078
-
Svidnik, Slovakia, 08901
- SL077
-
-
-
-
-
Alicante, Spain, 03690
- SP249
-
Barcelona, Spain, 08003
- SP176
-
Barcelona, Spain, 08028
- SP022
-
Barcelona, Spain, 08035
- SP021
-
Barcelona, Spain, 08036
- SP250
-
Ceuta, Spain, 51003
- SP019
-
Donostia, Spain, 20014
- SP194
-
Getxo, Spain, 48993
- SP222
-
Madrid, Spain, 28040
- SP018
-
Madrid, Spain, 28046
- SP093
-
Sant Cugat del Vallès, Spain, 08190
- SP184
-
Terrassa, Spain, 08221
- SP020
-
-
-
-
-
Kaohsiung, Taiwan, 833
- TA065
-
Taipei, Taiwan, 100
- TA086
-
Taoyuan, Taiwan, 333
- TA121
-
-
-
-
-
Bath, United Kingdom, BA1 3NG
- UK063
-
Blackpool, United Kingdom, FY2 0JH
- UK038
-
Cambridge, United Kingdom, CB21 5EF
- UK233
-
Cannock, United Kingdom, WS11 0BN
- UK033
-
Epping, United Kingdom, CM16 6TN
- UK211
-
Guildford, United Kingdom, GU2 7YD
- UK234
-
Leeds, United Kingdom, LS10 1DU
- UK055
-
London, United Kingdom, W1G 9JF
- UK039
-
Manchester, United Kingdom, M13 9NQ
- UK034
-
Norwich, United Kingdom, NR2 3TD
- UK229
-
Oxford, United Kingdom, OX3 9DU
- UK087
-
Plymouth, United Kingdom, PL5 8BT
- UK235
-
Sheffield, United Kingdom, S5 7JT
- UK100
-
Southampton, United Kingdom, SO16 6YD
- UK064
-
Southampton, United Kingdom, SO30 3JB
- UK152
-
Swindon, United Kingdom, SN3 6BW
- UK153
-
Warrington, United Kingdom, WA22 8WA
- UK154
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85005
- US112
-
Tucson, Arizona, United States, 85704
- US220
-
-
California
-
Encino, California, United States, 91436
- US168
-
Fullerton, California, United States, 92835
- US117
-
Los Angeles, California, United States, 90024
- US214
-
Pasadena, California, United States, 91105
- US189
-
Rancho Mirage, California, United States, 92270
- US096
-
Santa Ana, California, United States, 92705
- US0195
-
Simi Valley, California, United States, 93065
- US016
-
Temecula, California, United States, 92591
- US106
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
- US179
-
Norwich, Connecticut, United States, 06360
- US171
-
-
Florida
-
Atlantis, Florida, United States, 33462
- US088
-
Brooksville, Florida, United States, 34601
- US007
-
Hallandale Beach, Florida, United States, 33009
- US002
-
Hialeah, Florida, United States, 33012
- US140
-
Miami, Florida, United States, 33137
- US216
-
Miami, Florida, United States, 33165
- US110
-
North Palm Beach, Florida, United States, 33408
- US172
-
Orlando, Florida, United States, 32806
- US003
-
Pensacola, Florida, United States, 32502
- US256
-
Tampa, Florida, United States, 33613
- US037
-
Tampa, Florida, United States, 33613
- US042
-
The Villages, Florida, United States, 32162
- US004
-
-
Georgia
-
Atlanta, Georgia, United States, 30331
- US048
-
Atlanta, Georgia, United States, 30342
- US046
-
Columbus, Georgia, United States, 31909
- US217
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- US111
-
Shreveport, Louisiana, United States, 71104
- US095
-
-
Massachusetts
-
Newton, Massachusetts, United States, 02459
- US116
-
Quincy, Massachusetts, United States, 02169
- US174
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- US144
-
-
Nevada
-
Las Vegas, Nevada, United States, 89113
- US094
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- US135
-
Lawrenceville, New Jersey, United States, 08648
- US197
-
Manchester, New Jersey, United States, 08759
- US057
-
Mount Arlington, New Jersey, United States, 07856
- US215
-
Toms River, New Jersey, United States, 08755
- US209
-
West Long Branch, New Jersey, United States, 07764
- US036
-
-
New York
-
Albany, New York, United States, 12208
- US001
-
Brooklyn, New York, United States, 11235
- US049
-
New Hyde Park, New York, United States, 11040
- US097
-
New Windsor, New York, United States, 12553
- US177
-
New York, New York, United States, 10022
- US044
-
New York, New York, United States, 10021
- US142
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- US150
-
Charlotte, North Carolina, United States, 28270
- US185
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- US113
-
Cincinnati, Ohio, United States, 45227
- US008
-
Cincinnati, Ohio, United States, 45220
- US136
-
Shaker Heights, Ohio, United States, 44122
- US119
-
-
Oregon
-
Portland, Oregon, United States, 97210
- US134
-
-
Pennsylvania
-
Media, Pennsylvania, United States, 19063
- US169
-
Philadelphia, Pennsylvania, United States, 19102
- US187
-
Plains, Pennsylvania, United States, 18075
- US162
-
Willow Grove, Pennsylvania, United States, 19001
- US148
-
-
Texas
-
Houston, Texas, United States, 77074
- US115
-
San Antonio, Texas, United States, 78229
- US043
-
-
Utah
-
Orem, Utah, United States, 84058
- US143
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- US149
-
-
Washington
-
Spokane, Washington, United States, 99202
- US170
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subject with AD
- Ongoing donepezil therapy for AD
- An MMSE score 12 to 24 inclusive at Screening; MMSE score 10-26 inclusive at Baseline
- Hachinski Ischaemia score less than or equal to 4 at Screening.
- If female, subject must be: a. of non-childbearing potential or surgically sterile; or, b. willing to use an adequate methods of birth control. Male subjects who are sexually active will also be required to use an adequate form of birth control.
- Subject has the ability to comply with procedures for cognitive and other testing in the opinion of the investigator.
- Subject has a reliable caregiver who is willing to report on subject's status throughout the study.
Exclusion Criteria:
Other Causes for Dementia
- Diagnosis of vascular dementia
- Atypical clinical features or clinical course of dementia that would lead the investigator to conclude symptoms are more likely due to an alternate dementia diagnosis including, but not limited to, frontotemporal dementia, Lewy body dementia, or others.
Confounding Medical Conditions
- History of significant psychiatric illness such as schizophrenia or bipolar affective disorder or any other significant psychiatric illness that in the opinion of the investigator would interfere with participation in the study;
- Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: RVT-101
RVT-101 adjunct to 5 mg or 10 mg donepezil
|
once daily, oral, 35 mg tablets
|
|
Placebo Comparator: Placebo
Placebo adjunct to 5 mg or 10 mg donepezil
|
once daily, oral, pill manufactured to match RVT-101 35 mg tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24
Time Frame: Baseline, 24 weeks
|
The 11-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech.
The ADAS-Cog-11 total score range is from 0 to 70, with a higher score indicating more severe cognitive impairment.
|
Baseline, 24 weeks
|
|
Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24
Time Frame: Baseline, 24 weeks
|
The ADCS-ADL scale measures functional impairment in terms of activities of daily living.
The score ranges from 0 to 78.
The lower the score, the greater the impairment; higher scores indicate better (more desirable) function
|
Baseline, 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Global Impression of Change - Plus Caregiver Interview (CIBIC+) Score at Week 24
Time Frame: 24 weeks
|
The CIBIC+ assessment measures the global functioning of the subject.
The CIBIC+ is scored as a seven-point categorical rating, ranging from a score of 1 (indicating "very much improved"), to a score of 4 (indicating "no change"), or to a score of 7 (indicating "very much worse.")
Lower CIBIC+ scores indicate better (more desirable) function
|
24 weeks
|
|
The Dependence Scale (DS) Score Change From Baseline to Week 24
Time Frame: Baseline, 24 weeks
|
The DS measures the amount of assistance patients with dementia require in performing daily activities.
The scale consists of 13 items, representing a range of severity from mild to severe levels of dependency.
The score range is from 0 to 15 with higher scores indicating greater dependency.
|
Baseline, 24 weeks
|
|
Neuropsychiatric Inventory (NPI) Score Change From Baseline to Week 24
Time Frame: Baseline and Week 24
|
The NPI is a behavior rating scale composed of a 12-item structured interview of the caregiver that is scored from 0 to 144 (the higher the score, the greater the psychiatric disturbance).
It assesses 12 behavioral disturbances occurring in dementia patients: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor activity, night-time behavior disturbances, and eating disturbances.
Both the frequency and the severity of each behavior are determined.
|
Baseline and Week 24
|
|
ADAS-Cog-13 Score Change From Baseline to Week 24
Time Frame: Baseline, 24 weeks
|
13-item ADAS-Cog assesses a range of cognitive abilities including memory, comprehension, orientation in time and place, and spontaneous speech.
Most items are evaluated by tests, but some are dependent on clinician ratings on a 5-point scale.
The ADAS-Cog-13 is the ADAS-Cog-11 with 2 additional items: delayed word recall and total digit cancellation.
Scores for the ADAS-Cog-13 range from 0 to 85 with higher scores indicating greater dysfunction.
|
Baseline, 24 weeks
|
|
Measurement of Concentrations of RVT-101 (Intepirdine) in Plasma
Time Frame: Week 6, Week 12, Week 18, Week 24
|
Measurement collected at timepoints Week 6, Week 12, Week 18, and Week 24
|
Week 6, Week 12, Week 18, Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ilise Lombardo, MD, Axovant Sciences, Inc., Vice President, Clinical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
September 1, 2017
Study Completion (Actual)
September 1, 2017
Study Registration Dates
First Submitted
October 22, 2015
First Submitted That Met QC Criteria
October 22, 2015
First Posted (Estimate)
October 26, 2015
Study Record Updates
Last Update Posted (Actual)
December 5, 2018
Last Update Submitted That Met QC Criteria
November 8, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RVT-101-3001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of SaskatchewanCenter of Molecular Immunology, CubaNot yet recruitingMild Alzheimer's Disease | Moderate Alzheimer's DiseaseCanada
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...CompletedDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsCompletedDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; Alzheimer's Association; Alzheimer...Active, not recruitingPreclinical Alzheimer's Disease | Early Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedTerminatedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedTerminatedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Rutgers, The State University of New JerseyNational Institute on Aging (NIA)RecruitingAlzheimer's Disease (AD) | Healthy AgingUnited States
Clinical Trials on RVT-101
-
Axovant Sciences Ltd.TerminatedDementia With Lewy BodiesUnited States, Canada, France, Italy, Netherlands, Spain, United Kingdom
-
Axovant Sciences Ltd.CompletedDementia With Lewy BodiesUnited States, Canada, France, Italy, Netherlands, Spain, United Kingdom
-
Axovant Sciences Ltd.CompletedAlzheimer's Disease | Dementia With Lewy Bodies | Parkinson's Disease DementiaUnited States
-
Axovant Sciences Ltd.TerminatedAlzheimer's DiseaseUnited States, Argentina, Australia, Bulgaria, Canada, Chile, Croatia, Czechia, France, Germany, Italy, Korea, Republic of, Poland, Serbia, Singapore, Slovakia, Spain, Taiwan, United Kingdom
-
Immunovant Sciences GmbHTerminatedWarm Autoimmune Hemolytic AnemiaUnited States, Korea, Republic of, Israel, United Kingdom, Spain, Thailand
-
Dermavant Sciences GmbHCompletedAtopic DermatitisCanada, United States
-
Hoffmann-La RocheActive, not recruitingCrohn DiseaseUnited States, Belgium, Hungary, France, Poland, Canada, Bulgaria, Spain, Germany, Slovakia
-
Respivant Sciences GmbHRespivant Sciences Inc.CompletedRespiratory Morbidities of Prematurity (RMP)United States
-
Hoffmann-La RocheRecruitingModerately to Severely Active Crohns DiseaseTaiwan, Australia
-
Immunovant Sciences GmbHCompleted